Showing 2531-2540 of 3014 results for "".
- Novan: Positive Topline Results with Fungicidal SB208 in Phase 2 Trialhttps://practicaldermatology.com/news/nolan-positive-topline-results-with-fungicidal-sb208-in-phase-2-trial/2458222/Novan, Inc. has announced positive topline results from their Phase 2 clinical trial with SB208, a topical, silicone based-gel under development for the treatment of infections caused by dermatophytes such as Trichophyton rubrum, or T. rubrum. Novan’s SB208 Gel, at bo
- FDA Approves First Treatment for Rare Form of Skin Cancerhttps://practicaldermatology.com/news/fda-approves-first-treatment-for-rare-form-of-skin-cancer/2458236/The FDA granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. This is the first FDA-approved treatment for metastatic MCC, a r
- 5α-Reductase Inhibitors Not Associated with Increased Suicide Risk in Older Menhttps://practicaldermatology.com/news/5-reductase-inhibitors-not-associated-with-increased-suicide-risk-in-older-men/2458240/Using 5α- reductase inhibitors was not associated with increased suicide risk in a group of older men, according to new research in JAMA Internal Medicine. Risks f
- Rare Disease Breakthrough? New Treatment May Reduce Blistering in EBShttps://practicaldermatology.com/news/rare-disease-breakthrough-new-treatment-may-reduce-blistering-in-ebs/2458255/In a possible breakthrough in the treatment of epidermolysis bullosa simplex (EBS), Diacerein 1% ointment reduced blistering in patients with this rare genetic connective tissue disorder. The new findings were presented in a late-breaker session at the American Academy of Dermatology Annu
- Sandoz Proposed Biosimilar Shows Equivalent Efficacy to Humirahttps://practicaldermatology.com/news/sandoz-proposed-biosimilar-shows-equivalent-efficacy-to-humira/2458256/Sandoz’s proposed biosimilar adalimumab (GP2017) shows equivalent efficacy to reference medicine, according to data presented at the American Academy of Dermatology (AAD) in Orlando, Florida. The primary endpoint of the study was the proportio
- Skin Diseases Remain Major Cause of Disabilityhttps://practicaldermatology.com/news/skin-diseases-remain-major-cause-of-disability/2458267/Skin diseases are the fourth leading cause of disability worldwide, according to the Global Burden of Disease 2013 Study which appears online in JAMA Dermatology. For the study, researchers estimate
- Depression, Psoriasis And Risk Of Psoriatic Arthritis: What's the Connection?https://practicaldermatology.com/news/depression-psoriasis-and-risk-of-psoriatic-arthritis-whats-the-connection/2458269/Psoriasis patients who develop depression are at a 37 percent greater risk of developing psoriatic arthritis, compared with psoriasis patients who did not develop depression, according to a new
- Intramuscular Flu Shots May Mitigate Staph Risk In AD Patientshttps://practicaldermatology.com/news/intramuscular-flu-shots-may-be-better-for-ad-patients/2458290/Staphylococcus colonization of atopic dermatitis patients’ skin is associated with a weaker response to intradermal flu shots, according to a new study which suggests that intramuscular flu vaccines may be more effective in this group. The research, funded by the Natio
- Alma Lasers' Accent Celebrates 10 Years with a New Campaignhttps://practicaldermatology.com/news/alma-lasers-accent-celebrates-10-years-with-a-new-campaign/2458294/Accent Prime is celebrating a 10 year anniversary with a newly launched campaign. Alma Lasers released the first generation of the Accent branded platform in 2007, with the FDA approval, and technologically enhanced it throughout the pas
- Breaking Business News: ZO Skin Health, Inc. Acquires Refissa from Suneva Medicalhttps://practicaldermatology.com/news/business-news-zo-skin-health-inc-acquires-refissa-from-suneva-medical/2458298/ZO Skin Health, Inc. has acquired the worldwide rights to ReFissa as well as its generic equivalent tretinoin from Suneva Medical. Financial terms for the acquisition were not disclosed. ReFissa is the only